摘要
目的观察卡维地洛联合缬沙坦治疗慢性心力衰竭的临床疗效。方法选取我院2016年1月~2018年1月收治的慢性心力衰竭患者64例进行观察,全部患者随机分为观察组和对照组,每组32例,两组患者均予地高辛、利尿剂及纠正水、电解质平衡等常规治疗。观察组同时联合卡维地洛、缬沙坦治疗6个月。治疗后对比分析两组的总有效率及心功能指标LVEDD、LVESD、LVEF、CO治疗前后的变化情况。结果观察组患者治疗后的总有效率为96.88%,显著高于对照组,差异具有统计学意义(P<0.05),观察组患者治疗后的LVEDD、LVESD水平分别显著低于治疗前,LVEF、CO水平分别显著高于治疗前,差异具有统计学意义(P<0.05),且治疗后,观察组患者治的LVEDD、LVESD水平分别为(48.95±10.32) mm、(42.92±7.85) mm,分别显著低于对照组,LVEF、CO水平分别为(58.95±7.10)%、(52.89±8.13)L/min,分别显著高于对照组,差异具有统计学意义(P<0.05)。结论对慢性心力衰竭患者在积极对症治疗的同时应用卡维地洛联合缬沙坦治疗,有利于提高临床疗效,改善心功能,从而延长患者的生存期、提高生活质量。
Objective To observe the clinical efficacy of carvedilol combined with valsartan in the treatment of chronic heart failure. Methods 64 patients with chronic heart failure admitted to our hospital from January 2016 to January 2018 were enrolled. All patients were randomly divided into observation group and control group, with 32 cases in each group. Both groups were given digoxin, diuretics and routine treatment such as correcting water and electrolyte balance.The observation group was combined with carvedilol and valsartan for 6 months at the same time. After treatment, the total effective rate and cardiac function indexes of LVEDD, LVESD, LVEF and CO were compared between two groups before and after treatment. Results The total effective rate of the observation group was 96.88% after treatment, which was significantly higher than that of the control group. The difference was statistically significant(P<0.05). The LVEDD and LVESD levels in the observation group after treatment were significantly lower than those before treatment. The levels of LVEF and CO were significantly higher than those before treatment, and the difference was statistically significant(P<0.05). After treatment, the LVEDD and LVESD levels in the observation group were(48.95±10.32) mm and(42.92±7.85) mm, respectively, which were significantly lower than the control group. The LVEF and CO levels in the observation group after treatment were(58.95 ±7.10)% and(52.89±8.13) L/min, respectively, which were significantly higher than the control group. The difference between the two groups was statistically significant(P<0.05). Conclusion The application of carvedilol combined with valsartan in the treatment of patients with chronic heart failure is beneficial to improve clinical efficacy and improve cardiac function, thus prolonging patients’ survival and improving their quality of life.
作者
李心畅
吴迪
段庆辉
李迪
LI Xinchang;WU Di;DUAN Qinghui;LI Di(Department of Cardiology, Daqing Oilfield General Hospital, Daqing 163001, China)
出处
《中国现代医生》
2019年第20期54-56,共3页
China Modern Doctor
关键词
慢性心力衰竭
卡维地洛
缬沙坦
心功能
Chronic heart failure
Carvedilol
Valsartan
Cardiac function
